Anti-CEACAM-5 antibody drug conjugate - Sanofi SGN CEACAM5C
Alternative Names: Anti CEACAM 5 antibody drug conjugate - Sanofi/Seagen; PF-08046050; SAR-445953; SGN-CEACAM5CLatest Information Update: 15 Jun 2024
At a glance
- Originator Sanofi; Seagen
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates; Immunotherapies
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 03 Jun 2024 Phase-I clinical trials in Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Canada (IV) (NCT06131840)
- 10 Apr 2024 Efficacy and pharmacokinetics data from a preclinical trial in solid tumours presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 14 Dec 2023 Seagen has been acquired by Pfizer